Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicole LeBoeuf

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Pediatric Dermatology|October 26, 2007
The autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndromeNicole LeBoeuf, Amit Garg, Sophie Worobec
JAMA Oncology|October 13, 2022
Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysisAbdulhadi Jfri, Rachel Meltzer, Arash Mostaghimi, et al.
JAMA Dermatology|October 14, 2020
Fibroblast Growth Factor Receptor Inhibitors and Nonuremic CalciphylaxisJesse Hirner, James M Cleary, Anthony Sheets, et al.
JAMA Dermatology|November 7, 2019
Capecitabine-Related Eruption Mimicking Dermatomyositis in 2 Patients With Metastatic Breast CancerGabriela A Cobos, Caroline A Nelson, Abeer Alsarheed, et al.
Archives of Dermatology|March 21, 2012
Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanomaAllireza Alloo, Lilit Garibyan, Nicole LeBoeuf, et al.
Oral Diseases|October 24, 2019
Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case seriesMuhammad Ali Shazib, Sook-Bin Woo, Hervé Sroussi, et al.
Journal of the American Academy of Dermatology|January 30, 2024
Timing of cutaneous immune-related adverse events impacts survival in patients with cancer treated with immune-checkpoint inhibitors: A multi-institutional cohort studyHannah Rashdan, Shijia Zhang, Guihong Wan, et al.
Blood Advances|November 7, 2018
Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentratePavan K Bendapudi, Alissa Robbins, Nicole LeBoeuf, et al.
The Journal of Pediatrics|July 8, 2015
Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis BullosaMark B Geyer, Kavita Radhakrishnan, Roger Giller, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 8, 2015
A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapiesAlexandre Chan, Michael C Cameron, Benjamin Garden, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Pediatric Dermatology|October 26, 2007
The autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndromeNicole LeBoeuf, Amit Garg, Sophie Worobec
JAMA Oncology|October 13, 2022
Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysisAbdulhadi Jfri, Rachel Meltzer, Arash Mostaghimi, et al.
JAMA Dermatology|October 14, 2020
Fibroblast Growth Factor Receptor Inhibitors and Nonuremic CalciphylaxisJesse Hirner, James M Cleary, Anthony Sheets, et al.
JAMA Dermatology|November 7, 2019
Capecitabine-Related Eruption Mimicking Dermatomyositis in 2 Patients With Metastatic Breast CancerGabriela A Cobos, Caroline A Nelson, Abeer Alsarheed, et al.
Archives of Dermatology|March 21, 2012
Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanomaAllireza Alloo, Lilit Garibyan, Nicole LeBoeuf, et al.
Oral Diseases|October 24, 2019
Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case seriesMuhammad Ali Shazib, Sook-Bin Woo, Hervé Sroussi, et al.
Journal of the American Academy of Dermatology|January 30, 2024
Timing of cutaneous immune-related adverse events impacts survival in patients with cancer treated with immune-checkpoint inhibitors: A multi-institutional cohort studyHannah Rashdan, Shijia Zhang, Guihong Wan, et al.
Blood Advances|November 7, 2018
Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentratePavan K Bendapudi, Alissa Robbins, Nicole LeBoeuf, et al.
The Journal of Pediatrics|July 8, 2015
Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis BullosaMark B Geyer, Kavita Radhakrishnan, Roger Giller, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 8, 2015
A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapiesAlexandre Chan, Michael C Cameron, Benjamin Garden, et al.
Pageof 2